SCHEMBL5665366

SCHEMBL5665366

CCOP(=O)(OCC)C(c1cc(C)c(O)c(OC)c1)P(=O)(OCC)OCC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.52
HMGCR P04035 1/20 0.38
POLB P06746 2/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
ALOX5 P09917 4/20 0.36
PTGS2 P35354 3/20 0.35
FDPS P14324 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
GAA P10253 1/20 0.35
EGFR P00533 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6309425 0.76 L3MBTL1 (0.40) L3MBTL1POLBCA12CA1CA2
SCHEMBL6309420 0.76 L3MBTL1 (0.40) L3MBTL1POLBCA12CA1CA2
SCHEMBL5663296 0.75 L3MBTL1 (0.40) L3MBTL1KMT2AMEN1LMNA
SCHEMBL6307242 0.75 L3MBTL1 (0.40) L3MBTL1POLBSMN1; SMN2MAPTGAA
SCHEMBL5662451 0.75 L3MBTL1 (0.40) L3MBTL1HMGCRKMT2AMAPTCYP1A2
SCHEMBL6306977 0.75 L3MBTL1 (0.40) L3MBTL1POLBCA12CA1CA2
SCHEMBL6305868 0.75 L3MBTL1 (0.40) L3MBTL1CA12CA1CA2CA9
SCHEMBL5663721 0.74 FDPS (0.39) L3MBTL1FDPSKMT2AGAACYP1A2
SCHEMBL14665252 0.73 ALDH1A1 (0.41) ALOX5KMT2ASMN1; SMN2MAPTGAA
SCHEMBL6307777 0.73 L3MBTL1 (0.38) L3MBTL1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060205692-A1 1,1-and 1,2-Bisphosphonates as apoliprotein e modulators MONTES IMBER F 2006-09-14 US disclosed
EP-1506208-A4 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPOPROTEIN E MODULATORS ILEX PRODUCTS INC (US) 2006-05-24 EP disclosed
EP-1506208-A2 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPOPROTEIN E MODULATORS Ilex Products, Inc. (US) 2005-02-16 EP disclosed
WO-2003094851-A2 1,1- AND 1,2-BISPHOSPHONATES AS APOLIPROTEIN E MODULATORS ILEX PRODUCTS, INC. (US) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205692-A1 1,1-and 1,2-Bisphosphonates as apoliprotein e modulators APOB, APOL1, HDLBP L3MBTL1 1504/4885HMGCR 174/4885POLB 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.